-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Metastatic Breast Cancer Drug Details: DS-3939 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Non-Small Cell Lung Cancer Drug Details: DS-3939 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Pancreatic Ductal Adenocarcinoma Drug Details: DS-3939 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Metastatic Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Metastatic Ovarian Cancer Drug Details: DS-3939 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: DS-3939 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Metastatic Biliary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Metastatic Biliary Tract Cancer Drug Details: DS-3939 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onureg in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Mantle Cell Lymphoma Drug Details: Azacitidine (Onureg) is a pyrimidine analogue acts as...
-
Product Insights
![]()
Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Kidney Cancer Pipeline Products Market Report Overview Kidney cancer or renal cancer is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, anemia, shortness of breath, and bone pain. Treatment includes surgery, radiation therapy, and chemotherapy. The kidney cancer pipeline market research report provides comprehensive information on the therapeutics under development for kidney cancer, complete with analysis...
-
Product Insights
![]()
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
![]()
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Product Insights
![]()
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
![]()
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. The Small-Cell Lung Cancer market research report provides comprehensive information on the therapeutics under development for SCLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – FSH-GEX
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FSH-GEX Drug Details FSH-GEX is under development for the treatment of female infertility related...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – tomuzotuximab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tomuzotuximab Drug Details Cetuximab biobetter (GT-MAB 5.2-GEX, CetuGEX) is under development for treatment of...
-
Product Insights
![]()
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Head and Neck Cancer Pipeline Drugs Market Report Overview Head and Neck Cancer symptoms include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. Treatment includes chemotherapy and radiation therapy. The Head and Neck Cancer pipeline drugs market research report provides an analysis of the Head and Neck Cancer drugs by stage of development, drug target, mechanism of action (MoA), route...
-
Product Insights
![]()
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastric Cancer signs and symptoms include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Treatment includes surgery, chemotherapy, and radiation therapy. The Gastric Cancer pipeline drugs market research report provides an analysis of the Gastric Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and...
-
Product Insights
![]()
Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Esophageal cancer symptoms include cough, difficulty swallowing, chest pain, pressure or burning, and weight loss. Predisposing factors include age, smoking, obesity, and bile reflux. Treatment includes chemotherapy, radiation therapy, and surgery. The Esophageal Cancer pipeline drugs market research report provides an overview of the Esophageal Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA),...
-
Product Insights
![]()
Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Women Infertility pipeline market report provides a comprehensive overview of the therapeutics under development for Women Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Women Infertility and features...
-
Sector Analysis
![]()
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.
-
Sector Analysis
![]()
OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2024
The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.